Pfizer Inc (PFE)

$25.19 +0.15 (0.60%)
Market Cap 143.22B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 7.87
Forward PE 8.02
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 87,589,900
Avg Vol 69,926,156
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 16%
Beta 0.46
Analysts Sell
Price Target $27.95

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
taxplanr
taxplanr Dec. 21 at 2:59 PM
Surely they are not thinking about self amplifying malignantRNA in vaccines or pets or agriculture $BNTX $MRNA $PFE $MRK https://www.malone.news/p/bioweapons-treaty-update-progress
0 · Reply
Cedenmo
Cedenmo Dec. 21 at 12:51 PM
$BMY Feeling VERY bullish for BMY, $MRK $PFE in 2026. The first two are already gaining at end of 2025.
0 · Reply
Longbuy1
Longbuy1 Dec. 21 at 11:27 AM
$SLS buy our AML drugs $PFE 10 billion. 45$ a share.
1 · Reply
1iquid
1iquid Dec. 21 at 2:34 AM
💎 Liquid® Live Actionable Trade Asset: $PFE Contracts: $PFE January 15, 2027 $27 Calls Scale in: $1.47- $1.80 Scale out: $5.71-$9.79 Profit Potential : 126% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Judykay
Judykay Dec. 21 at 2:26 AM
$PFE https://youtu.be/rMOvdrungQM?si=ocFNVovCX1WWgPnN👀
0 · Reply
Stockwatcher9999
Stockwatcher9999 Dec. 20 at 10:48 PM
$ARVN -im long here but i am a little confused why neither arvinas or $PFE wants to commercialize vepdeg. I totally get why arvinas doesnt want too but curious if i missed anything here.
1 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Dec. 20 at 9:15 PM
$PFE new additional drugs and discounts that may further pressure the group Medicare enrollees to pay 50% less for some drugs in 2026, report says REUTERS Dec-19-2025 12:59 p.m. ET * AARP study looks at first 10 drugs negotiated under IRA * Finds 7 of the drugs will cost under $100 in 2026 * Analyzes plans in California, Florida, Texas, New York, Pennsylvania * Savings stem from lower coinsurance based on negotiated prices By Ahmed Aboulenein WASHINGTON, Dec 18 (Reuters) - Americans enrolled in Medicare will pay ‌about 50% less out of pocket in 2026 for some drugs including Pfizer (PFE) and Bristol Myers Squibb's (BMY) blood thinner Eliquis and ​Merck & Co's diabetes drug Januvia, a study in the five most populous U.S. states suggested.
0 · Reply
MetalinMaybach
MetalinMaybach Dec. 20 at 7:20 PM
$PFE NGENF is getting ready to list with Nasdaq very soon. This is mainly focused in the SCI space but has applications in other CNS diseases as shown in preclinical trials. If it lists this will be a good opportunity to capitalize on benefits of more exposure.
0 · Reply
taxplanr
taxplanr Dec. 20 at 6:32 PM
Study of C19 malignantRNA from $BNTX $MRNA $PFE that was pulled...Is now peer reviewed and published Mitochondrial dysregulation causes adverse events and cancer https://www.wjgnet.com/2220-315X/full/v15/i4/113869.htm?appgw_azwaf_jsc=XSsQAHpGE0gW0eW7lCV3VQuN59eDZ8W5CVSlCb9UmRp0qIqinbv3Tba-jeFZylShQjtLrYotIFkoIhO1p6A46BFOz9Jm4m3VADjPejeGRFfivtWomv2tp4W6NHWZ0CBzBNd34-MbG7Lh2t8j_m9rX9qfbsDH-cjyENQHW7X4lCZYHdaFu7oaJEbfiTyio024llDLl4U6S7zzLrqQU8d20AV4KwTeJnWc0WQ5FXyrMDOZ5d4bPV8XaYwXILrB20zWakN0RkON35s4qm_xADl-AUU336Xe_YK6pwqeJ9Jtfvl3xJFhqKZ0IUIuQvLmIiWZ4z4RvZNwZXICt21xqOMZYA
0 · Reply
SignalVampire7
SignalVampire7 Dec. 20 at 4:25 PM
$PFE big pharma grinding a low range, yield plus pipeline keep bids under it but it still needs a resistance break to wake up
0 · Reply
Latest News on PFE
Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Dec 19, 2025, 11:45 AM EST - 1 day ago

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 1 day ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY GILD LLY MRK

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Dec 18, 2025, 10:00 AM EST - 3 days ago

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

Dec 18, 2025, 6:58 AM EST - 3 days ago

Pfizer Plays Catchup In Obesity Market, Licenses Weight-loss Drug From Fosun

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 3 days ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN BMY LLY NVS

Pfizer Stock Can Sink More. Here Is How

Dec 17, 2025, 2:36 PM EST - 3 days ago

Pfizer Stock Can Sink More. Here Is How

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

Dec 17, 2025, 10:14 AM EST - 4 days ago

Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back

MRK

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Dec 17, 2025, 6:45 AM EST - 4 days ago

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Dec 16, 2025, 2:39 PM EST - 4 days ago

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Pfizer falls on disappointing guidance

Dec 16, 2025, 12:33 PM EST - 4 days ago

Pfizer falls on disappointing guidance

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Dec 16, 2025, 10:12 AM EST - 5 days ago

Pfizer's modest 2026 outlook shows its big investments will take time to pay off

Here's why Pfizer is revising its revenue forecasts

Dec 16, 2025, 7:47 AM EST - 5 days ago

Here's why Pfizer is revising its revenue forecasts

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Dec 16, 2025, 7:25 AM EST - 5 days ago

Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales.

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Dec 16, 2025, 7:16 AM EST - 5 days ago

Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Dec 16, 2025, 6:54 AM EST - 5 days ago

Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Dec 16, 2025, 6:45 AM EST - 5 days ago

Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

Dec 15, 2025, 8:24 AM EST - 6 days ago

Adaptive Biotechnologies signs non-exclusive deals with Pfizer worth up to $890 million

ADPT

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

Dec 15, 2025, 8:00 AM EST - 6 days ago

Adaptive Biotechnologies Announces Two Immune Receptor Licensing Agreements with Pfizer

ADPT

Pfizer Declares First-Quarter 2026 Dividend

Dec 12, 2025, 12:00 PM EST - 8 days ago

Pfizer Declares First-Quarter 2026 Dividend

Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends

Dec 12, 2025, 8:45 AM EST - 9 days ago

Dividend Harvesting Portfolio Week 249: $24,900 Allocated, $2,646.53 In Projected Dividends

AMLP MO MSTY OHI

Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial

Dec 12, 2025, 7:24 AM EST - 9 days ago

Health Rounds: Pfizer drug delays progression of advanced breast cancer in trial

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

Dec 10, 2025, 11:38 AM EST - 10 days ago

Pfizer to cut hundreds of jobs in Switzerland to reduce costs, Bloomberg News reports

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Dec 10, 2025, 8:15 AM EST - 11 days ago

TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer

Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?

Dec 9, 2025, 3:30 PM EST - 11 days ago

Will Pfizer's YaoPharma deal deliver a powerful new oral obesity pill?

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

Dec 9, 2025, 11:14 AM EST - 11 days ago

Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill

Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons

Dec 9, 2025, 10:59 AM EST - 11 days ago

Undisclosed Deaths in the Pfizer mRNA COVID-19 Vaccine Trial Discussed in the Journal of American Physicians and Surgeons

Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains

Dec 9, 2025, 10:45 AM EST - 11 days ago

Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains

Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500

Dec 9, 2025, 10:15 AM EST - 12 days ago

Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500

AES AMCR ARE CAG CPB D DOC

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Dec 9, 2025, 6:55 AM EST - 12 days ago

Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement

Pfizer partners with YaoPharma for weight management treatment

Dec 9, 2025, 6:38 AM EST - 12 days ago

Pfizer partners with YaoPharma for weight management treatment

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

Dec 9, 2025, 6:30 AM EST - 12 days ago

Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Dec 6, 2025, 5:15 PM EST - 14 days ago

HYMPAVZI® (marstacimab) Reduced Bleeds by 93% Compared to On-Demand Treatment in Adults and Adolescents with Hemophilia A or B with Inhibitors

Pfizer: The Market Is Still Wrong About It

Dec 5, 2025, 9:00 AM EST - 16 days ago

Pfizer: The Market Is Still Wrong About It

17 dividend-stock bargains from a value manager with a stellar track record

Dec 2, 2025, 12:11 PM EST - 18 days ago

17 dividend-stock bargains from a value manager with a stellar track record

BMY CIVI CMCSA CVS MOS MRK MTH

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

Dec 1, 2025, 3:50 PM EST - 19 days ago

FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks

BNTX MRNA NVAX

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

Dec 1, 2025, 12:35 PM EST - 19 days ago

Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men

BNTX MRNA NVAX

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

Dec 1, 2025, 10:00 AM EST - 20 days ago

Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance

Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters

Nov 30, 2025, 6:13 AM EST - 21 days ago

Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters

Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December

Nov 29, 2025, 11:59 PM EST - 21 days ago

Pfizer, Mastercard Among 24 Companies To Announce Annual Increases In December

MA AVGO

8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills

Nov 28, 2025, 11:00 AM EST - 22 days ago

8 'Safer' Dividend Buys In Barron's 23 Better November Bets Than T-Bills

BBB BBY BMY CAG EQR KEY KIM

Final Trade: DAL, AXP, PFE, HMY

Nov 26, 2025, 6:20 PM EST - 24 days ago

Final Trade: DAL, AXP, PFE, HMY

AXP DAL HMY

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

Nov 26, 2025, 12:30 PM EST - 24 days ago

Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings

VALN

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

Nov 25, 2025, 5:20 AM EST - 26 days ago

JNJ Stock vs. PFE Stock: Which Pharmaceutical Giant Is A Better Buy?

JNJ

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Nov 21, 2025, 1:24 PM EST - 4 weeks ago

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Pfizer Crosses Below Key Moving Average Level

Nov 20, 2025, 4:05 PM EST - 4 weeks ago

Pfizer Crosses Below Key Moving Average Level

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

Nov 20, 2025, 11:17 AM EST - 4 weeks ago

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

AMGN BMY GILD IVV MRK SPY VOO

October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs

Nov 19, 2025, 5:43 PM EST - 4 weeks ago

October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs

CAG CIM EPD HAFN HRL IPG KEY

Pfizer: Is This Pharma Giant Finally A Bargain

Nov 19, 2025, 3:51 PM EST - 4 weeks ago

Pfizer: Is This Pharma Giant Finally A Bargain

Pfizer in $41.5 million settlement with Texas over ADHD drug

Nov 19, 2025, 10:31 AM EST - 4 weeks ago

Pfizer in $41.5 million settlement with Texas over ADHD drug

Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 6:58 AM EST - 4 weeks ago

Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript

taxplanr
taxplanr Dec. 21 at 2:59 PM
Surely they are not thinking about self amplifying malignantRNA in vaccines or pets or agriculture $BNTX $MRNA $PFE $MRK https://www.malone.news/p/bioweapons-treaty-update-progress
0 · Reply
Cedenmo
Cedenmo Dec. 21 at 12:51 PM
$BMY Feeling VERY bullish for BMY, $MRK $PFE in 2026. The first two are already gaining at end of 2025.
0 · Reply
Longbuy1
Longbuy1 Dec. 21 at 11:27 AM
$SLS buy our AML drugs $PFE 10 billion. 45$ a share.
1 · Reply
1iquid
1iquid Dec. 21 at 2:34 AM
💎 Liquid® Live Actionable Trade Asset: $PFE Contracts: $PFE January 15, 2027 $27 Calls Scale in: $1.47- $1.80 Scale out: $5.71-$9.79 Profit Potential : 126% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
Judykay
Judykay Dec. 21 at 2:26 AM
$PFE https://youtu.be/rMOvdrungQM?si=ocFNVovCX1WWgPnN👀
0 · Reply
Stockwatcher9999
Stockwatcher9999 Dec. 20 at 10:48 PM
$ARVN -im long here but i am a little confused why neither arvinas or $PFE wants to commercialize vepdeg. I totally get why arvinas doesnt want too but curious if i missed anything here.
1 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Dec. 20 at 9:15 PM
$PFE new additional drugs and discounts that may further pressure the group Medicare enrollees to pay 50% less for some drugs in 2026, report says REUTERS Dec-19-2025 12:59 p.m. ET * AARP study looks at first 10 drugs negotiated under IRA * Finds 7 of the drugs will cost under $100 in 2026 * Analyzes plans in California, Florida, Texas, New York, Pennsylvania * Savings stem from lower coinsurance based on negotiated prices By Ahmed Aboulenein WASHINGTON, Dec 18 (Reuters) - Americans enrolled in Medicare will pay ‌about 50% less out of pocket in 2026 for some drugs including Pfizer (PFE) and Bristol Myers Squibb's (BMY) blood thinner Eliquis and ​Merck & Co's diabetes drug Januvia, a study in the five most populous U.S. states suggested.
0 · Reply
MetalinMaybach
MetalinMaybach Dec. 20 at 7:20 PM
$PFE NGENF is getting ready to list with Nasdaq very soon. This is mainly focused in the SCI space but has applications in other CNS diseases as shown in preclinical trials. If it lists this will be a good opportunity to capitalize on benefits of more exposure.
0 · Reply
taxplanr
taxplanr Dec. 20 at 6:32 PM
Study of C19 malignantRNA from $BNTX $MRNA $PFE that was pulled...Is now peer reviewed and published Mitochondrial dysregulation causes adverse events and cancer https://www.wjgnet.com/2220-315X/full/v15/i4/113869.htm?appgw_azwaf_jsc=XSsQAHpGE0gW0eW7lCV3VQuN59eDZ8W5CVSlCb9UmRp0qIqinbv3Tba-jeFZylShQjtLrYotIFkoIhO1p6A46BFOz9Jm4m3VADjPejeGRFfivtWomv2tp4W6NHWZ0CBzBNd34-MbG7Lh2t8j_m9rX9qfbsDH-cjyENQHW7X4lCZYHdaFu7oaJEbfiTyio024llDLl4U6S7zzLrqQU8d20AV4KwTeJnWc0WQ5FXyrMDOZ5d4bPV8XaYwXILrB20zWakN0RkON35s4qm_xADl-AUU336Xe_YK6pwqeJ9Jtfvl3xJFhqKZ0IUIuQvLmIiWZ4z4RvZNwZXICt21xqOMZYA
0 · Reply
SignalVampire7
SignalVampire7 Dec. 20 at 4:25 PM
$PFE big pharma grinding a low range, yield plus pipeline keep bids under it but it still needs a resistance break to wake up
0 · Reply
1iquid
1iquid Dec. 20 at 7:48 AM
OptionWizards Tip (education only): Use a risk/reward ratio of at least 1:2 when trading options on stocks like PANW, TXN, or PFE to guide your strategy. $PANW $TXN $PFE Not financial advice.
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 20 at 6:58 AM
Enter: $PFE Calls Strike Price: $26 Expiry Date: JAN 09 2026 Buy in Price: $0.26 - $0.29 Sell Price: $0.54 Profit : +107% (Turn every $1 into $2.07) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
cc10socr
cc10socr Dec. 20 at 3:51 AM
$PFE still making 20-40 dollars a week wheel trading this
0 · Reply
taxplanr
taxplanr Dec. 20 at 3:41 AM
The $BNTX $MRNA $PFE legacy https://www.tiktok.com/t/ZTrtc8RfK/
1 · Reply
Sjs360
Sjs360 Dec. 20 at 12:07 AM
$PFE bag holding at $30.51
1 · Reply
OnlyInItForTheMoney
OnlyInItForTheMoney Dec. 19 at 11:45 PM
$PFE $ELTP No rumors.
0 · Reply
Tfizzle
Tfizzle Dec. 19 at 11:33 PM
$PFE let’s wake up to a 26 monday am price!
2 · Reply
KingdomTrading
KingdomTrading Dec. 19 at 11:17 PM
$PFE Current: $25.19 Entry: $25.38 Target: $24.78 Potential: -2.4% Horizon: 14 days The content provided on https://stocksurger.com/ is for informational purposes only and does not constitute a recommendation to buy or sell any security.
0 · Reply
Micheal_Pothead
Micheal_Pothead Dec. 19 at 9:05 PM
$PFE we love huge AH trades that don’t move the price whatsoever!
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Dec. 19 at 9:00 PM
$PFE - SEC be like:
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Dec. 19 at 8:57 PM
$PFE - Typical McHedgie McCrooky McFuckery
0 · Reply
Tiger65
Tiger65 Dec. 19 at 8:50 PM
$PFE they should really send for the SEC to examine what’s going on here. This is kind of criminal. Huge spreads to the downside.
1 · Reply